Skip to main content
. 2022 Feb 7;322(3):E307–E318. doi: 10.1152/ajpendo.00234.2021

Figure 1.

Figure 1.

Pharmacological inhibition of neprilysin with sacubitril reduces streptozotocin (STZ)-induced hyperglycemia without altering body weight and insulin sensitivity. Plasma neprilysin (A) and DPP-4 (B) activities at baseline (week 0) and at the end of the 8-week study period in vehicle (VEH)- or streptozotocin (STZ)-injected male Glp1r+/+ mice fed a high-fat diet (HFD) alone or supplemented with sacubitril (SAC). n = 13–18/group, *P ≤ 0.05 (analyzed using two-way ANOVA followed by Dunnet or Sidak’s multiple comparisons test). Random fed blood glucose levels (C) and body weight (D) over time in VEH-CTL (open circles, n = 13), STZ-CTL (black circles, n = 18) and STZ-SAC (gray triangles, n = 17) groups of male Glp1r+/+ mice. *P ≤ 0.05 STZ-CTL vs. VEH-CTL; #P ≤ 0.05 STZ-SAC vs. STZ-CTL (analyzed using repeated-measures two-way ANOVA/mixed effects followed by Dunnet’s multiple comparisons test). E: blood glucose levels as percentage of baseline during an IPITT at the end of the 8-wk treatment period in VEH-CTL (open circles, n = 13), STZ-CTL (black circles, n = 18), and STZ-SAC (gray triangles, n = 17) male Glp1r+/+ mice. *P ≤ 0.05 STZ-CTL vs. VEH-CTL (analyzed using repeated-measures two-way ANOVA followed by Dunnet’s multiple comparisons test). Data are means ± SE.